Supernus Pharmaceuticals (SUPN) Gains from Investment Securities (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Gains from Investment Securities data on file, last reported at $2.4 million in Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $2.4 million, down 28.43% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.7 million (up 90.69% YoY), and the FY2025 annual result was -$1.9 million, down 169.43% from the prior year.
• Gains from Investment Securities grew to $2.4 million in Q1 2026 per SUPN's latest filing, from -$6.1 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $34.6 million in Q4 2023 and troughed at -$37.6 million in Q4 2024.
• A 5-year average of -$467800.0 and a median of $27000.0 in 2022 frame the typical range for Gains from Investment Securities.
• On a YoY basis, Gains from Investment Securities climbed as much as 247328.57% in 2023 and fell as far as 9207.41% in 2023.
• A 5-year view of Gains from Investment Securities shows it stood at -$14000.0 in 2022, then surged by 247328.57% to $34.6 million in 2023, then tumbled by 208.71% to -$37.6 million in 2024, then jumped by 83.83% to -$6.1 million in 2025, then jumped by 139.31% to $2.4 million in 2026.
• Business Quant data shows SUPN's Gains from Investment Securities at $2.4 million in Q1 2026, -$6.1 million in Q4 2025, and $3.3 million in Q1 2025.